Clinical Trials Logo

Cardiac Fibrosis clinical trials

View clinical trials related to Cardiac Fibrosis.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05317806 Active, not recruiting - Cardiac Fibrosis Clinical Trials

Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency

Start date: October 10, 2022
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy and safety of metformin, in patients 18-65 years of age with homozygous plasminogen activator inhibitor-1 (PAI-1) deficiency, with or without cardiac fibrosis, for a period of 60 months. The starting dose of metformin will be 500 mg up to a maximum dose of 2000 mg for a period of 5 years with the aim to assess the safety and efficacy of metformin on prevention/stabilization or regression of cardiac fibrosis in a Treated population vs. a Comparison population.

NCT ID: NCT02921321 Active, not recruiting - Clinical trials for Musculoskeletal Diseases

Pilot Study of Cardiac MR in Patients With Muscular Dystrophy

Start date: January 2014
Phase:
Study type: Observational

Muscular Dystrophy can affect the skeletal muscles and also the heart and breathing muscles, causing significant morbidity and mortality. As patients are now living longer, treatment of muscular dystrophies involves drugs that help improve heart function. However, better types of heart imaging studies are needed to understand how these treatments work. Researchers want to improve heart imaging to identify earlier indicators of heart dysfunction in muscular dystrophy patients and how these are changed by medical treatment. The new imaging indicators will also help identify candidates for entry into future clinical trials.